Table 2 Changes occurred in the quantitative mitogen-induced IFNγ responses from QFT-GIT taken at the different time points during treatment with TNF antagonists.

From: Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases

 

QFT-GIT (IU/mL) results during biological treatment

Baseline*

1 year

2 years

4 years

8 years

All patients (n = 15)

6.3 (2.7–16.9)

11.2 (8.09–14.6)

15.7 (10–30.4)

6.3 (0.98–15.8)

14.2 (13–16.9)

Indeterminate results (n)

0

0

1

2

0

Etanercept (n = 10)

7.4 (2.7–19.3)

11.03 (4.8–24.5)

15.1 (9.6–30.5)

2.07 (0.7–12.9)

13.8 (11.7–16.9)

Adalimumab (n = 5)

5.06 (2.6–8.9)

11.8 (8.6–14.3)

20.5 (8.5–31.3)

8.4 (5.2–16)

14.3 (9.9–18.5)

RA (n = 7)

6.3 (2.7–16.9)

11.2 (2.6–12.7)

12.2 (8.7–15.7)

1.4 (0.4–6.9)

14.2 (13–17.7)

PsA (n = 8)

5.7 (2.8–16.8)

11.5 (9.1–15.9)

29.5 (12.6–31)

13.9 (4.7–15.9)

14.02 (7.8–16.8)

  1. *Prior to the onset of biological treatment. The values expressed as IU/ml are median with interquartile range.
  2. Note: QFT-GIT = QuantiFERON-TB Gold In-Tube; RA = rheumatoid arthritis; PsA = psoriatic arthritis.
Back to article page